Niemann-Pick Disease Type C Market
DelveInsight’s ‘Niemann-Pick
Disease Type C (NPC) - Market Insights, Epidemiology and Market Forecast-2027’ report
delivers an in-depth understanding of the disease, historical & forecasted
epidemiology as well as the market trends of Niemann-Pick Disease Type C (NPC)
in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom),
and Japan.
The Report provides the current treatment practices, emerging drugs having the
potential to get launched in the forecast period, market share of the
individual therapies, current and forecasted market size of Niemann-Pick
Disease Type C (NPC) from 2016 to 2027 segmented by seven major markets. The
Report also covers current treatment practice/algorithm, market drivers, market
barriers and unmet medical needs to curate best of the opportunities and assess
underlying potential of the market.
Geography Covered
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United
Kingdom)
- Japan
Study Period:
2016-2027
Niemann-Pick Disease Type C (NPC) - Disease Understanding and Treatment Algorithm
The DelveInsightNiemann-Pick Disease Type C (NPC) market report gives the thorough understanding of the Niemann-Pick Disease Type C (NPC) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Niemann-Pick Disease Type C (NPC) in the US, Europe, and Japan.
Niemann-Pick Disease Type C (NPC) Epidemiology
The Niemann-Pick Disease Type C (NPC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by total prevalent patient population, diagnosed population, sub-types specific cases (NPC1 and NPC 2) and clinical distribution of NPC by phenotypes (early infantile, late infantile, juvenile and adult).
According to DelveInsight, the total prevalent population of NPC was found to be 2,099 in the year 2016 in 7MM.
Niemann-Pick Disease Type C (NPC) Drug Chapters
This segment of the Niemann-Pick Disease Type C (NPC) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The drugs marketed for the treatment mainly includes Substrate Reduction Therapy – Zavesca [Miglustat; Actelion] and Supportive Therapies for the management of symptoms associated with NPC - Antiepileptics (Seizures); Tricyclic Antidepressants & CNS Stimulants (Cataplexy); Anticholinergics, Trihexyphenydil& GABA Derivatives (Dystonia & Tremor); atypical antipsychotics (Psychosis). Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [VTS-270 (Mallinckrodt), Arimoclomol (Orphazyme), and TrappsolCyclo (CTD Holdings, Inc.) have been covered in the report.
Niemann-Pick Disease Type C (NPC) Market Outlook
The Niemann-Pick Disease Type C (NPC) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Niemann-Pick Disease Type C (NPC) was estimated to be USD 27.61 billion in 2016.
Niemann-Pick Disease Type C (NPC) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Niemann-Pick Disease Type C (NPC) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
Niemann-Pick Disease Type C (NPC) Report Insights
Niemann-Pick Disease Type C (NPC) - Disease Understanding and Treatment Algorithm
The DelveInsightNiemann-Pick Disease Type C (NPC) market report gives the thorough understanding of the Niemann-Pick Disease Type C (NPC) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Niemann-Pick Disease Type C (NPC) in the US, Europe, and Japan.
Niemann-Pick Disease Type C (NPC) Epidemiology
The Niemann-Pick Disease Type C (NPC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by total prevalent patient population, diagnosed population, sub-types specific cases (NPC1 and NPC 2) and clinical distribution of NPC by phenotypes (early infantile, late infantile, juvenile and adult).
According to DelveInsight, the total prevalent population of NPC was found to be 2,099 in the year 2016 in 7MM.
Niemann-Pick Disease Type C (NPC) Drug Chapters
This segment of the Niemann-Pick Disease Type C (NPC) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The drugs marketed for the treatment mainly includes Substrate Reduction Therapy – Zavesca [Miglustat; Actelion] and Supportive Therapies for the management of symptoms associated with NPC - Antiepileptics (Seizures); Tricyclic Antidepressants & CNS Stimulants (Cataplexy); Anticholinergics, Trihexyphenydil& GABA Derivatives (Dystonia & Tremor); atypical antipsychotics (Psychosis). Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [VTS-270 (Mallinckrodt), Arimoclomol (Orphazyme), and TrappsolCyclo (CTD Holdings, Inc.) have been covered in the report.
Niemann-Pick Disease Type C (NPC) Market Outlook
The Niemann-Pick Disease Type C (NPC) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Niemann-Pick Disease Type C (NPC) was estimated to be USD 27.61 billion in 2016.
Niemann-Pick Disease Type C (NPC) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Niemann-Pick Disease Type C (NPC) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
Niemann-Pick Disease Type C (NPC) Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment
Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report
will help to develop Business Strategies by understanding the trends
shaping and driving the Niemann-Pick Disease Type C (NPC) market
- Organize sales and marketing efforts by identifying the
best opportunities for Niemann-Pick Disease Type C (NPC) market
- To understand the future market competition in the
Niemann-Pick Disease Type C (NPC) market
Comments
Post a Comment